PRESS-RELEASE ·Filed May 5, 2026
Press release · FDA
Actionable Insight • Neutral
The June 2026 DIAMOND topline readout is the primary catalyst; watch for efficacy and safety data that could validate OCS-01 as first topical DME therapy.
Final — all horizons settled through T+60d
OCS ▼ -59.60% at T+60d
NEUTRAL call -59.60% · α vs SPY -62.34% · entry $27.75 → $11.21
T+1d
+6.59%
call +6.59% · α +5.21%
$29.58
settled 6mo ago
T+5d
+9.59%
call +9.59% · α +7.60%
$30.41
settled 6mo ago
T+20d
-55.71%
call -55.71% · α -60.67%
$12.29
settled 5mo ago
T+60d
-59.60%
call -59.60% · α -62.34%
$11.21
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Oculis presented DME AWARE Delphi study results at ARVO 2026, reinforcing unmet need for non-invasive early DME treatment, supporting OCS-01's potential. Topline Phase 3 DIAMOND results expected June 2026.
Key Facts
- DME AWARE Delphi study presented at ARVO 2026
- Experts reached consensus on need for non-invasive options for early DME intervention
- OCS-01 Phase 3 DIAMOND topline results expected June 2026
- 40% of DME patients have inadequate response to anti-VEGF injections
- 60% of DME patients remain untreated one year after diagnosis
Financial Impact
No direct financial impact; topline readout in June 2026 is key catalyst
Risk Factors
- Phase 3 failure or underwhelming data
- Competition from existing injectables and other topical candidates
- Regulatory and commercial adoption uncertainty
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287391 |
13 reports for OCS
75% Hit rate @ T+5 Went positive at some point 4 of 4 best @ T+5▲ +50.63%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 6-K | $8.76 $8.66 | ▼ −1.14% | ▼ −2.44% | $8.03 (−8.33%) |
Aug 10, 2026 11w ago | 6-K | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $8.03 (−37.07%) |
Aug 10, 2026 11w ago | Press Release | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $8.03 (−37.07%) |
Jun 11, 2026 19w ago | Press Release | $11.00 $11.30 | ▲ +2.73% | ▲ +2.29% | $8.03 (−27.00%) |
Jun 9, 2026 20w ago | Press Release | $10.98 $11.61 | ▲ +5.74% | ▲ +3.33% | $8.03 (−26.87%) |
May 29, 2026 21w ago | Press Release | $22.71 $11.21 | ▲ +50.63% | ▲ +48.10% | $8.03 (+64.63%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $8.03 (−73.59%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $8.03 (−73.59%) |
May 7, 2026 24w ago | Press Release | $31.09 $31.37 | ▲ +0.90% | ▼ −0.60% | $8.03 (−74.17%) |
May 5, 2026 25w ago | Press Release | $27.75 $30.41 | ▲ +9.59% | ▲ +7.60% | $8.03 (−71.06%) |
Showing 10 of 13
US Market Status
Market Open — Closes in 3h 41m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers